Share on Pinterest Researchers say brain lesions don’t appear to be connected to severe disability in multiple sclerosis. SeventyFour/Getty Images About 1 million people in the United States live with ...

BUFFALO, N.Y. — For decades, clinicians treating multiple sclerosis (MS) have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging (MRI) scans as a sign that a ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

Roche RHHBY announced new data from the mid-stage study on an experimental candidate, fenebrutinib, for treating relapsing multiple sclerosis (“RMS”). Fenebrutinib is an investigational oral, ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

Roche Holdings AG's RHHBY Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib ...

"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

FRANKFURT, May 17 (Reuters) - Roche ROG.S said on Wednesday that its multiple sclerosis drug candidate, part of a class of compounds that has been linked to cases of liver damage, reduced brain ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis ...

Christina Applegate opened up about the symptoms she’s experienced throughout her battle with Multiple Sclerosis (MS) during a recent podcast interview on Monday, March 25. The sitcom star, 52, was ...